This dynamic program on the treatment of low-grade upper tract urothelial carcinoma (UTUC) with JELMYTO® (mitomycin) for pyelocaliceal solution will feature a presentation of key data from the pivotal trial and more recently published real-world data. In addition, an expert panel of urologists will discuss two unique patient types and consider appropriate treatment options, administration, and how to manage adverse reactions.
